Pooled HELIOS-A/HELIOS-B safety included 707 patients (30.3% hereditary; remainder wild-type) with median 33.4 months of therapy and exposure up to 58 months. Exposure-adjusted overall and serious ...
No new safety signals observed at Year 5 in the POETYK PSO long-term extension trial, consistent with the established Sotyktu safety profile Following five years of continuous Sotyktu treatment, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results